| 13821 |
Soluble Interleukin-2 Receptor (sIL-2), Tumor Necrosis Factor Alpha (TNF-α)and its Receptor as Prognostic Markers in Non-Hodgkin,s Lymphoma. |
Department of Clinical Pathology |
1999 |
| 13822 |
Soluble Interleukin-2 Receptor (sIL-2), Tumor Necrosis Factor Alpha (TNF-α)and its Receptor as Prognostic Markers in Non-Hodgkin,s Lymphoma. |
Department of Clinical Pathology |
1999 |
| 13823 |
Soluble Interleukin-2 Receptor (sIL-2), Tumor Necrosis Factor Alpha (TNF-α)and its Receptor as Prognostic Markers in Non-Hodgkin,s Lymphoma. |
Department of Rheumatology ,Rehabilitation & physical medicine |
1999 |
| 13824 |
some Hormonal Aspects of β-Thalassmic Children in Assiut |
Department of Clinical Pathology |
1999 |
| 13825 |
Some international approaches to aminoglycoside monitoring in the extended dosing interval era. |
Department of Pharmacology |
1999 |
| 13826 |
Spotlight on the continual applicability of routine plasma monitoring antiepileptic drugs in the treatment of epilepsy. |
Department of Pharmacology |
1999 |
| 13827 |
Spotlight on the continual applicability of routine plasma monitoring antiepileptic drugs in the treatment of epilepsy. |
Department of Neurology and Psychiatry |
1999 |
| 13828 |
Spotlight on the continual applicability of routine plasma monitoring antiepileptic drugs in the treatment of epilepsy. |
Department of Public Health and Community Medicine |
1999 |
| 13829 |
Spotlight on the continual applicability of routine plasma monitoring antiepileptic drugs in the treatment of epilepsy. |
Department of Pharmacology |
1999 |
| 13830 |
Study of some angiogenic stimulators in rheumatoid arthritis: Impact of therapy with gold & methotrexate. |
Department of Biochemistry |
1999 |
Do you have any questions? 
